 Home > Active Ingredient News > Antitumor Therapy > Piqray, the first and only drug targeting PIK3CA mutant breast cancer, has been approved in Europe.

Piqray, the first and only drug targeting PIK3CA mutant breast cancer, has been approved in Europe.

 Last Update: 2020-08-06
 Source: Internet
 Author: User

Tags

7 1 2 inches

1 2 dimethoxyethane

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Novartis announced that the European Commission (EC) has approved the combination of Piqisib with the fluorois group for the treatment of male patients with local lysatary advanced or metastatic breast cancer who are positive in hormone receptors and human epidermal growth factor receptor 2 negative (HR/HER2-), PIK3CA mutations, progression of disease after endocrine monodrug treatment, and postmenopausal female patients.
Piqray is the first and only approved drug for patients with advanced breast cancer with PIK3CA mutations.
334,000 people worldwide are diagnosed with advanced breast cancer each year, and about 40% of patients with HR/HER2-subtype have a PIK3CA mutation.
the approval was based on the positive results of the Phase III SOLAR-1 test, and the Piqray and Fluves group combinationneared the median progression-free survival (PFS) (5.7 and 11.0 months, respectively) and more than doubled the overall response rate compared to the fluvews group single use.
Photo Source: Novartis's official website Piqray is an inhibitor of phosplyinininol-3-kinase (PI3K), mainly for PI3K alpha (PIK3CA).
PIK3CA mutation causes THE ACTIVATION of PI3K alpha and Akt signals, stimulates tumor growth and is closely related to patient prognosis.
Photo Source: Novartis.com

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.